Get the Stockscreener App
0.00
100.00%
-1.26
After Hours:
1.00
1.00
+
Sonnet Biotherapeutics Holdings Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
See More
Previous Close:
$1.26
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$8.60M
Revenue:
$129.20K
Net Income/Loss:
$-7.44M
P/E Ratio:
0.00
EPS:
-11.19
Net Cash Flow:
$-8.62M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$19.30
Sonnet Biotherapeutics Holdings Inc Stock (SONN) Company Profile
Name
Sonnet Biotherapeutics Holdings Inc
Sector
Industry
Phone
609-375-2227
Address
100 OVERLOOK CENTER, PRINCETON, NJ
Compare SONN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SONN
Sonnet Biotherapeutics Holdings Inc
|
0.00 | 8.60M | 129.20K | -7.44M | -8.62M | -11.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Sonnet Biotherapeutics Holdings Inc Stock (SONN) Latest News
Ideas Watch: Should I hold or sell Sonnet BioTherapeutics Holdings Inc stock in 2025Weekly Profit Summary & Community Trade Idea Sharing Platform - moha.gov.vn
Breakout Move: Will Sonnet BioTherapeutics Holdings Inc stock benefit from automationEarnings Growth Summary & Verified Momentum Stock Ideas - moha.gov.vn
Head to Head Comparison: Sonnet BioTherapeutics (NASDAQ:SONN) & BioXcel Therapeutics (NASDAQ:BTAI) - Defense World
Why Sonnet BioTherapeutics Holdings Inc. stock is a must watch in 2025 - Улправда
Can Sonnet BioTherapeutics Holdings Inc. stock maintain growth trajectoryEarnings Growth Summary & Weekly Top Gainers Alerts - Улправда
Will Sonnet BioTherapeutics Holdings Inc. stock deliver better than expected guidanceBear Alert & Free Verified High Yield Trade Plans - Улправда
Will Sonnet BioTherapeutics Holdings Inc. stock benefit from automationJuly 2025 Earnings & AI Optimized Trading Strategy Guides - DonanımHaber
Is Sonnet BioTherapeutics Holdings Inc. stock a defensive play in 20252025 Fundamental Recap & Weekly Sector Rotation Insights - DonanımHaber
Will Sonnet BioTherapeutics Holdings Inc. stock maintain growth storyTrade Signal Summary & Real-Time Market Sentiment Reports - DonanımHaber
Sonnet BioTherapeutics (NASDAQ: SONN) updates FHAB-based oncology pipeline - Stock Titan
Sonnet BioTherapeutics Holdings: Net loss of $16.0M on $1.0M revenue, with urgent need for new funding to sustain operations - TradingView — Track All Markets
Sonnet BioTherapeutics (NASDAQ:SONN) Shares Down 67.3% – Here’s Why - Defense World
What analysts say about Sonnet BioTherapeutics Holdings Inc stockMarket Timing Techniques & Low Cost Wealth Building - earlytimes.in
Lowenstein Represents Sonnet BioTherapeutics In Closing Of Business Combination With Hyperliquid Strategies - Mondaq
Officer Kenney Acquires 233,374 Of Sonnet BioTherapeutics Holdings Inc [SONN] - TradingView
Hyperliquid Strategies Moves $411M in HYPE to Hypercore - Live Bitcoin News
Will HYPE extend rally as Hyperliquid Strategies Inc. begins staking? - FXStreet
Sonnet BioTherapeutics Stockholders Greenlight Hyperliquid Strategies Merger Deal - Blockonomi
Sonnet’s $1B Hype Treasury Signals Ambitious Digital Asset Expansion After Merger Approval - Crypto Economy
Sonnet BioTherapeutics Merges with Hyperliquid Strategies - TipRanks
Biotech Trio Gets Hammered On Heavy Trading - Finimize
Is Sonnet BioTherapeutics Holdings Inc. stock attractive for hedge fundsWeekly Trend Summary & Real-Time Buy Zone Alerts - Newser
Sonnet BioTherapeutics Holdings, Inc. (SONN) Stock: Merges Into Hyperliquid Era with Nasdaq Debut as PURR - parameter.io
Sonnet BioTherapeutics Enters a New Frontier with a $1 Billion HYPE Digital Asset Treasury - OneSafe
Sonnet BioTherapeutics shareholders approve proposed business merger with Hyperliquid Strategies Inc. - Bitget
Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination - GlobeNewswire
Hyperliquid (HYPE) May Revisit $59 Soon Amid Extreme Market Fear: Here is Why - Coinpedia Fintech News
HYPE news live: price surges after merger nod — faces resistance at $36.22, range-bound outlook - Traders Union
Sonnet BioTherapeutics Approves Merger with Hyperliquid and Rorschach - MSN
Sonnet BioTherapeutics Holdings, Inc. (SONN) Stock: Shareholders Approve Hyperliquid Merger, Setting Stage for $1B HYPE Treasury - CoinCentral
Revolutionary Shift: How Sonnet BioTherapeutics Became a $305M Digital Asset Treasury Powerhouse - CryptoRank
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Sonnet shareholders approve Hyperliquid merger to launch HYPE-focused crypto treasury - Crypto Briefing
Stockholders Approve Sonnet–Hyperliquid Merger - citybiz
Sonnet shareholders approve merger for potential $1 billion HYPE crypto treasury - The Block
Sonnet BioTherapeutics (SONN) Stockholders Approve Business Comb - GuruFocus
Sonnet Biotherapeutics Holdings announces stockholder approval of proposed business combination with Hyperliquid Strategies - marketscreener.com
Sonnet BioTherapeutics shareholders approve business combination - Investing.com
Sonnet BioTherapeutics shareholders approve business combination By Investing.com - Investing.com Australia
Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Business Combination - TradingView
Sonnet BioTherapeutics Stockholders Approve Business Combination with Hyperliquid Strategies Inc and Rorschach I LLC - Quiver Quantitative
Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder - GlobeNewswire
Sonnet BioTherapeutics (NASDAQ: SONN) gets stockholder OK for Hyperliquid Strategies business combination - Stock Titan
Is Sonnet BioTherapeutics Holdings Inc. stock attractive for passive investorsJuly 2025 Rallies & Stepwise Entry/Exit Trade Alerts - Newser
Sonnet BioTherapeutics (SONN) Stock Analysis Report | Financials & Insights - Benzinga
Sonnet BioTherapeutics Holdings, Inc.(NasdaqCM:SONN) dropped from NASDAQ Composite Index - marketscreener.com
What drives Sonnet BioTherapeutics Holdings Inc stock priceTrading Psychology Tips & Start Learning With Our Courses - earlytimes.in
Healthy Upside Potential: Sonnet BioTherapeutics Holdings Inc (SONN) - setenews.com
Sonnet BioTherapeutics (NASDAQ:SONN) Shares Up 3.2% – Should You Buy? - Defense World
Regression analysis insights on Sonnet BioTherapeutics Holdings Inc. performanceMarket Sentiment Report & AI Based Trade Execution Alerts - newser.com
Why Sonnet BioTherapeutics Holdings Inc. stock could benefit from AI revolution2025 Market Outlook & Weekly High Conviction Ideas - newser.com
Sonnet Biotherapeutics Holdings Inc Stock (SONN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):